Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Saliv...
Actuate Therapeutics, Inc. - Common stock (ACTU)
Company Research
Source: GlobeNewswire
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3ß expression may help identify patients most likely to respond to treatment of a historically difficult-to-treat refractory disease CHICAGO and FORT WORTH, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3ß), today announced the publication of new data in Clinical Cancer Research from a Phase II study (NCT05010629) evaluating elraglusib in combination with carboplatin or cisplatin (with or without sequential pembrolizumab priming) in patients with advanced, metastatic salivary gland cancers, including adenoid cystic carcinoma and other subtypes. The peer-reviewed paper (PMID: 41065505), en
Show less
Read more
Impact Snapshot
Event Time:
ACTU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACTU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACTU alerts
High impacting Actuate Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ACTU
News
- How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% [Yahoo! Finance]Yahoo! Finance
- Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Actuate Therapeutics (NASDAQ:ACTU) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ACTU
Earnings
- 11/13/25 - Beat
ACTU
Sec Filings
- 12/11/25 - Form 144
- 11/28/25 - Form 8-K
- 11/28/25 - Form 424B5
- ACTU's page on the SEC website